Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER...
Transcript of Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER...
![Page 1: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/1.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 1 / 27
Slide 2 / 27
Page 1
![Page 2: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/2.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 3 / 27
Slide 4 / 27
Page 2
![Page 3: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/3.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 5 / 27
Slide 6 / 27
Page 3
![Page 4: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/4.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 7 / 27
Slide 8 / 27
Page 4
![Page 5: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/5.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 9 / 27
Slide 10 / 27
Page 5
![Page 6: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/6.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 11 / 27
Slide 12 / 27
Page 6
![Page 7: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/7.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 13 / 27
Slide 14 / 27
Page 7
![Page 8: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/8.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 15 / 27
Slide 16 / 27
Page 8
![Page 9: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/9.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 17 / 27
Slide 18 / 27
Page 9
![Page 10: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/10.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 19 / 27
Slide 20 / 27
Page 10
![Page 11: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/11.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 21 / 27
Slide 22 / 27
Page 11
![Page 12: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/12.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 23 / 27
Slide 24 / 27
Page 12
![Page 13: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/13.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 25 / 27
Slide 26 / 27
Page 13
![Page 14: Slide 2 / 27 · Slide 9 / 27 Slide 10 / 27 Page 5. undefined S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE](https://reader033.fdocuments.us/reader033/viewer/2022060517/604a9e4e99b8eb1272718e79/html5/thumbnails/14.jpg)
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 27 / 27
Page 14